AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Elucidating the Role of the Microbiome in Cutaneous T Cell Lymphoma

Description

In this presentation, Alan Zoe, an Assistant Professor of Dermatology at Northwestern, discusses the significant role of the microbiome in cutaneous T cell lymphoma (CTCL), an inflammatory skin disease and cancer. He highlights the unique link between CTCL and the microbial environment, noting that patients often experience severe immune dysregulation and higher risks of infections, particularly from staphylococcus bacteria. Clinical evidence suggests that antibiotic treatments can reduce the severity of CTCL and that certain bacterial species, like Staphylococcus aureus, can enhance malignant T cell activity. Zoe presents findings from their research, which includes a comparison of the microbiome in CTCL patients and healthy controls, noting shifts in bacterial diversity and specific changes linked to disease severity. The research also indicates differences in microbiome composition among racial groups, particularly higher staphylococcal levels in African American patients, which could contribute to worse outcomes. Future therapeutic strategies may involve targeting these microbial imbalances with topical treatments that minimize harmful bacteria while potentially harnessing beneficial microbes. Overall, the interplay between the microbiome and CTCL represents a promising area of research that could lead to novel treatment approaches.

View more

Conclusions

  • Advanced cutaneous T cell lymphoma (CTCL) patients exhibit significant immune dysregulation which significantly increases their risk of infections and mortality.
  • CTCL is closely linked to microbial communities, especially with high colonization by Staphylococcus aureus which may worsen patient outcomes.
  • Antibiotic therapy has shown potential to reduce disease severity in CTCL, suggesting a therapeutic role of microbiome modulation.
  • There are racially influenced disparities in CTCL sepsis rates, particularly among African Americans, highlighting the need for targeted healthcare approaches.
  • The gut microbiome in CTCL patients exhibits decreased diversity and a loss of beneficial taxa as disease severity progresses, which may correlate with immune dysregulation.
  • Microbial shifts in the CTCL skin microbiome reflect disease severity and can potentially predict treatment responsiveness.
  • Staphylococcal toxins may contribute to treatment resistance in CTCL by stimulating malignant T cell activity.
  • Identifying and modulating specific microbial communities may provide novel therapeutic strategies for CTCL management.
  • CTCL patients show altered nasal and gut microbiomes, which may influence disease dynamics and treatment outcomes.
  • Future therapies could include engineered commensals that target tumor antigens or manipulate the microbiome to enhance treatment efficacy in CTCL.
  • Agar NS et al. JCO. 2010;28:4730-4739.
  • Mourad A, et al. JID. 2020;2:495-497.
  • Lindahl et al, Blood 2019; JAAD 2008; Talpur et al, Br J Dermatol 2008; Fanok et al, JID 2018.
  • Hooper MJ ... Zhou XA, JAAD Feb 2023.
  • Nguyen M ... Zhou XA, Arch Dermatol Res Mar 2023.
  • Salava et al. JID 2020; Dehner et al. JID Innov 2022; Krejsgaard et al, Blood 2014; Willerslev-Olsen et al, Toxins 2013; Blümel et al, Oncoimmunology 2019; Jackow et al, Blood 1997.
  • Vadivel et al, Blood 2024.
  • Hooper MJ ... Zhou XA, JID Innovations Apr 2022.
  • Hooper MJ ... Zhou XA, JEADV Sep 2022.
  • Hooper MJ ... Zhou XA, Frontiers in Immunology Nov 2022.
  • Chen YE et al. Science Apr 2023.